Navigation Links
Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Date:6/7/2011

FORT WORTH, Texas, June 7, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at two upcoming investment conferences.  The first presentation is scheduled for 2:30 pm(EDT) on Thursday, June 9, 2011 during the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York, NY. The second is scheduled for 10:15 am (EDT) on Thursday, June 23, 2011 during the 2011 Wells Fargo Securities Healthcare Conference at The InterContinental Boston in Boston, MA.

The presentations will include updates on the Company's ongoing commercial operations, its recent acquisition of Regranex® Gel and phase 2b summary results for its cell therapy pipeline candidate for chronic wounds (HP802-247).

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is presently centered around next-generation cell-based therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.


'/>"/>
SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
2. Healthpoint Launches New Corporate Identity
3. Healthpoint to Present at 29th Annual J.P. Morgan Healthcare Conference
4. Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada
5. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
6. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
7. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
8. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
9. Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial
10. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
11. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Guide to ... , No matter on which side of the Atlantic devicemakers do business, ... regulations they have to follow. , In addition to the full text of the ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton School’s ... mid-market executives as a kick-off to the fifth annual CEO Connection Mid-Market Convention. ... the University of Pennsylvania campus, followed by the two-day convention, which will target ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
Breaking Medicine News(10 mins):